OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative)

Cancer Investigation

Volumn 26, Issue 3, 2008, Pages 222-229

  García Tuñón, Ignacio ^a   Ricote, Monica ^a   Ruiz, Antonio ^b   Fraile, Benito ^a   Paniagua, Ricardo ^a   Royuela, Mar ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Breast cancer; LIF; LIFR ; OSM; OSMR

Indexed keywords

GLYCOPROTEIN GP 130; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR; LEUKEMIA INHIBITORY FACTOR RECEPTOR BETA; ONCOSTATIN M; ONCOSTATIN M RECEPTOR BETA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST LESION; CANCER INFILTRATION; CARCINOMA IN SITU; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; BLOTTING, WESTERN; BREAST NEOPLASMS; CARCINOMA IN SITU; CYTOKINE RECEPTOR GP130; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKEMIA INHIBITORY FACTOR; MIDDLE AGED; ONCOSTATIN M; RECEPTORS, OSM-LIF;

EID: 40149088953     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701638491     Document Type: Article

References (23)